Trius Therapeutics, Inc.
Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its most important drug in development, is an IV- and orally-administered antibiotic with a potential to treat antibiotic-resistant strains of staph infections, known as MRSA (methicillin-resistant Staphylococcus aureus). Until the company is able to sell torezolid phosphate to hospitals and other health care providers, the company is primarily funded by government grants, research contracts, and collaboration agreements. The company filed for an initial public offering in November 2009.
Contact Details
Office Address
Trius Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA, USA 92121
Phone: (858) 452-0370
Fax: (858) 677-9975
Executives
Chairman
David S. Kabakoff
President, CEO, and Director
Jeffrey Stein